© 2015

BRAF Targets in Melanoma

Biological Mechanisms, Resistance, and Drug Discovery

  • Ryan J.¬†Sullivan

Part of the Cancer Drug Discovery and Development book series (CDD&D, volume 82)

Table of contents

  1. Front Matter
    Pages i-viii
  2. Suraj Venna, Sekwon Jang, Michael B. Atkins
    Pages 1-23
  3. Jennifer A. Lo, David E. Fisher
    Pages 25-45
  4. Melissa A. Wilson, Katherine L. Nathanson
    Pages 47-65
  5. Jeffrey A. Sosman, Douglas B. Johnson
    Pages 67-84
  6. Pallavi Kumar, Ryan J. Sullivan
    Pages 85-103
  7. Zachary A. Cooper, Zain Ahmed, Jennifer A. Wargo
    Pages 163-182
  8. Keith T. Flaherty
    Pages 183-201
  9. Back Matter
    Pages 203-204

About this book


This volume contains a collection of writings from the leaders in the fields of Molecular Biology and Melanoma Research which will begin to tell the ever-expanding story of the most recent findings, discoveries, and potential of BRAF-directed targets in melanoma. Recent research has shown that BRAF inhibitors are effective for a short period of time, but there is little hope that these drugs as single agents will lead to durable benefit in a majority of patients. Among scientists and researchers who work in drug discovery, there is a lot of interest in the development of molecularly targeted cancer agents. Namely, the identification of a molecular target, the selection of molecules which effectively inhibit this target. What is starkly different about the development of this class of compounds, however, is that the mechanism of action of these agents are not as straightforward as was once previously assumed and the mechanisms of resistance that tumor cells employ to evade complete destruction are unlike any that have been described before. These discoveries in addition to utilization of modern molecular biology techniques have led to a series of hypotheses regarding which other types of molecules could be used in combination with BRAF-inhibitors in hopes of revolutionizing the potential of therapeutics in melanoma.


BRAF-inhibitors Next-Gen Sequencing immunotherapy p53 vemurafenib

Editors and affiliations

  • Ryan J.¬†Sullivan
    • 1
  1. 1.Center for MelanomaMassachusetts General Hospital Cancer CenterBostonUSA

About the editors

Dr. Ryan J. Sullivan is affiliated with Massachusetts General Hospital and Dana Farber. His research interests are in the development of novel molecular therapeutic agents for Kaposi sarcoma (KS) and malignant melanoma and the translation of promising preclinical findings into early stage clinical trials. He serves as the co-director of the Eugene Michael Egan Melanoma Translational Research Laboratory at Beth Israel Deaconess Medical Center (BIDMC) and is actively investigating promising biomarkers of response and benefit to immunotherapy and molecular targeted therapy for patients with melanoma.

Bibliographic information

  • Book Title BRAF Targets in Melanoma
  • Book Subtitle Biological Mechanisms, Resistance, and Drug Discovery
  • Editors Ryan J. Sullivan
  • Series Title Cancer Drug Discovery and Development
  • Series Abbreviated Title Cancer Drug Discovery,Development
  • DOI
  • Copyright Information Springer Science+Business Media New York 2015
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine Medicine (R0)
  • Hardcover ISBN 978-1-4939-2142-3
  • Softcover ISBN 978-1-4939-5348-6
  • eBook ISBN 978-1-4939-2143-0
  • Series ISSN 2196-9906
  • Series E-ISSN 2196-9914
  • Edition Number 1
  • Number of Pages VIII, 204
  • Number of Illustrations 5 b/w illustrations, 21 illustrations in colour
  • Topics Cancer Research
    Molecular Medicine
    Medical Microbiology
  • Buy this book on publisher's site